Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy

Mekaru, Harutaka; Lü, Jie; Tamanoi, Fuyuhiko

doi:10.1016/j.addr.2015.09.009

Cited by 240 publications

(149 citation statements)

References 99 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…The straightforward synthesizing process enables the scaled-up manufacture of MSN for inhalation exposure test assays11. Thus, aPM 2.5 particles were prepared with MSN as the core and three chemical species loaded into the pores of MSN.…”

Section: Resultsmentioning

confidence: 99%

“…Mesoporous silica nanoparticles (MSN) are advantageous for harboring the major chemical components of PM 2.5 because of their special structure with numerous small pores; these chemicals can adhere to the large inner surface of the pores11. Previous studies have reported that the primary injury associated with airborne particulate matter exposure is mainly localized in the respiratory system, causing inflammation and a reduction in lung function129, and the health effects is largely associated with the oxidative potential (OP) of PM 2.5 particles12.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Polydatin protects the respiratory system from PM2.5 exposure

Yan

Wang

Tie

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Atmospheric particle is one of the risk factors for respiratory disease; however, their injury mechanisms are poorly understood, and prevention methods are highly desirable. We constructed artificial PM2.5 (aPM2.5) particles according to the size and composition of actual PM2.5 collected in Beijing. Using these artificial particles, we created an inhalation-injury animal model. These aPM2.5 particles simulate the physical and chemical characteristics of the actual PM2.5, and inhalation of the aPM2.5 in rat results in a time-dependent change in lung suggesting a declined lung function, injury from oxidative stress and inflammation in lung. Thus, this aPM2.5-caused injury animal model may mimic that of the pulmonary injury in human exposed to airborne particles. In addition, polydatin (PD), a resveratrol glucoside that is rich in grapes and red wine, was found to significantly decrease the oxidative potential (OP) of aPM2.5 in vitro. Treating the model rats with PD prevented the lung function decline caused by aPM2.5, and reduced the level of oxidative damage in aPM2.5-exposed rats. Moreover, PD inhibited aPM2.5-induced inflammation response, as evidenced by downregulation of white blood cells in bronchoalveolar lavage fluid (BALF), inflammation-related lipids and proinflammation cytokines in lung. These results provide a practical means for self-protection against particulate air pollution.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Polydatin protects the respiratory system from PM2.5 exposure

Yan

Wang

Tie

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Another strategy is by the exposure of magnetic particles to oscillating magnetic field resulting in heat generation due to superparamagnetic property, where this temperature increase can be used to allow opening of a nanovalve, further triggering the drug release. [61] DNA-assembled gold-nanorod superstructures are also applied to tune the drug loading and releasing process due to its unique NIR induced photothermal effect. [62] These stimuli-responsive nanomedicines can precisely control the spatio-temporal drug release that offers the possibility to protect the drugs from degradation, allows direct localization or release of the payloads, and facilitates the maximum release at the target tissue/cell.…”

Section: Second Generation Nanomedicinesmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

“…[52] Additionally, controlled release is being investigated in MSNs because they can be chemically modified due to their stability and because MSN synthesis is relatively facile. [53] The synthesis of MSNs begins with one of two precursors: either tetraalkooxysilanes or sodium silicate solutions. Different templating agents such as ionic surfactants, pluronic surfactants, and neutral block copolymers are further used to influence pore size and arrangement as well the MSN's general shape and size.…”

Section: Mesoporous Silica-based Nanoparticlesmentioning

confidence: 99%

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

RNA interference through the use of short interfering molecules known as short interfering RNA (siRNA) has the potential to greatly advance research in treatments for many diseases because it has the ability to silence the expression of specific genes by helping degrade target mRNA. However, challenges to siRNA delivery have made the development of safe and effective delivery systems paramount in siRNA research. Various types of delivery systems have been proposed and investigated for siRNA delivery and therapy. Although viral vectors have been established to be the most effective in delivering siRNA molecules, they also raise many concerns over biosafety, especially concerning immunogenicity. Therefore, many researchers have begun to investigate and study non-viral vectors. Non-viral vectors are studied because they are typically considered to be safer than viral vectors albeit less efficient as well. The three general non-viral vectors that have been studied for siRNA delivery are lipid-based, non-lipid organic-based, and non-lipid inorganic-based carriers. Within those general parameters of non-viral vector classification are subtypes that are each unique with their own characteristic benefits and downsides. Many of these carriers, as well as even naked siRNA, do have the potential to be modified so that siRNA delivery could be further enhanced with benefits such as greater stability and duration. Researchers still must be wary with alterations as to not interfere with siRNA function. Currently, widespread siRNA therapeutics are still out of reach, but as more advancements in siRNA research including research on their delivery mechanisms are established, the goal of integrating siRNA therapy into the treatment of a multitude of diseases becomes increasingly more of a possibility. Researchers are currently investigating how siRNA can be used to not just treat cancer but ocular and neurodegenerative diseases as well as many others. There are still many obstacles to face and overcome before siRNA therapy can be implemented into the treatment of many diseases, and more research must still be conducted concerning siRNA delivery systems. Many advancements pertaining to siRNA carriers have been made, and many more are likely on their way.

show abstract

Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy

Cited by 240 publications

References 99 publications

Polydatin protects the respiratory system from PM2.5 exposure

Polydatin protects the respiratory system from PM2.5 exposure

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

An Overview of Various Carriers for siRNA Delivery

Contact Info

Product

Resources

About